Lassen Therapeutics

About:

Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.

Website: https://lassentherapeutics.com/

Top Investors: Catalio Capital Management, Frazier Life Sciences, Alta Partners, Longitude Capital, Frazier Healthcare Partners

Description:

Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The company’s lead candidate is LASN01, a monoclonal antibody targeting IL-11 receptor alpha (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis, and blocking its activity has the potential to be more effective than targeting other factors such as TGF-β and CTGF. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells.